JenaValve
ApprovedYou can finally give high-risk patients with severe, symptomatic aortic regurgitation (AR) an FDA-approved transcatheter aortic valve replacement (TAVR) treatment option. Trilogy’s locator technology ensures commissural alignment and allows the valve to attach to the native leaflets for secure anchoring, even in the absence of calcium.
About
You can finally give high-risk patients with severe, symptomatic aortic regurgitation (AR) an FDA-approved transcatheter aortic valve replacement (TAVR) treatment option. Trilogy’s locator technology ensures commissural alignment and allows the valve to attach to the native leaflets for secure anchoring, even in the absence of calcium.
Funding History
5Total raised: $297M
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile